Clinical Trials Logo

Clinical Trial Summary

To determine if treatment with cisplatin and radiation followed by carbo and taxol reduces the rate of recurrence when compared to sandwich therapy.


Clinical Trial Description

To determine if treatment with cisplatin and volume-directed radiation followed by carboplatin and paclitaxel for 4 cycles (experimental arm) reduces the rate of recurrence (increases recurrence-free survival) when compared to sandwich therapy (control arm). To determine if treatment with cisplatin and volume-directed radiation followed by carboplatin and paclitaxel for 4 cycles (experimental arm) reduces the rate of death (increases survival) when compared to sandwich therapy (control arm). To compare the regimens with respect to tolerability and acute and late adverse effects of therapy. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02501954
Study type Interventional
Source Women's Cancer Care Associates, LLC
Contact
Status Completed
Phase Phase 3
Start date March 2015
Completion date November 2023

See also
  Status Clinical Trial Phase
Completed NCT01010126 - Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Phase 2
Completed NCT01935973 - Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer Phase 1
Active, not recruiting NCT03660826 - Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone Phase 2
Completed NCT01642082 - Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer Phase 2
Completed NCT01440998 - Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer Phase 1
Completed NCT02728258 - Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer Phase 2
Active, not recruiting NCT00977574 - Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer Phase 2
Completed NCT01225887 - Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer Phase 2
Completed NCT01005329 - Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer Phase 2
Recruiting NCT05256225 - Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma Phase 2/Phase 3
Withdrawn NCT03836157 - Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer Phase 2
Suspended NCT04585958 - Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Endometrial Cancer Phase 1
Active, not recruiting NCT02142803 - TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors Phase 1
Active, not recruiting NCT00807768 - Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Phase 3
Completed NCT01307631 - Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer Phase 2
Active, not recruiting NCT02065687 - Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Phase 2/Phase 3
Active, not recruiting NCT02874430 - Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer Phase 2
Completed NCT01210222 - Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer Phase 2
Active, not recruiting NCT00942357 - Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Phase 3
Completed NCT01132820 - Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer Phase 2